New Delhi, Sept 10 (PTI) Over 90 per cent of Gen Zs surveyed in India believe that visual communication skills

Chatbots can facilitate ‘cognitive offloading,’ or taking shortcuts when learning. But emerging research on AI and cognitive science shows that learning is like a workout.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has entered into an agreement to acquire icometrix, a company focused on providing AI-powered brain imaging analysis for neurological disorders such as Alzheimer’s disease to meet the growing demand for MRI in personalized treatment planning. To complement its MR-guided AI-assisted scanning expertise with analysis and reporting in neurological disease assessment, GE HealthCare expects to integrate the icometrix icobrain p

NEW YORK--(BUSINESS WIRE)--Cognitiv, the leading advanced performance partner powered by deep learning, today launched a major upgrade to ContextGPTTM, bringing new levels of precision to contextual audience targeting. AI now provides an unprecedented breadth of world knowledge, depth of page-level comprehension, and the ability to reason about audiences and intent, and Cognitiv is leading the way by applying that power to contextual targeting. The platform is now up to 40% more accurate in conn

If treated as an ongoing rather than a sporadic process, change can be embraced as a foundational attribute of an organization’s entrepreneurial culture.

New Mexico is becoming the first state in the U.S. to offer free early childhood education to every family.

Advisory Alpha LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 16.8% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,431 shares of the company’s stock after buying an additional 1,215 shares during the quarter. Advisory Alpha LLC’s [...]

Plato Investment Management Ltd decreased its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 35.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 78,605 shares of the biopharmaceutical company’s stock after selling 43,619 shares during the period. [...]

The global schizophrenia market is experiencing significant growth momentum, valued at USD 8.29 billion in 2024 and projected to reach USD 13.41 billion by 2032, representing a compound annual growth rate (CAGR) of 5.49% during the forecast period of 2024-2032.

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 24 - 26, 2025 in Barcelona, Spain. Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: ECTRIMS 2025 PROGRAMME. Details of the upcoming presentations are outlined below.TG PRESENTATIONS:Oral Presentation: Long-term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from Six Years of ULTIMATE I and II Open-label ExtensionPresentation Date/Time: Wednesday, September 24th at 14:55 – 15:05 CEST (8:55am ET – 9:05am ET)Session: Free Communication 2: Therapeutic interventions - from trials to real-world evidence – Lecture Hall 117Abstract Number: ECTRIMS25-1571Lead Author: Dr. Bruce Cree - Weill Institute for Neurosciences, University of California, San Francisco, CA, United StatesePoster Presentation: Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates from the ENHANCE StudyDate/Time: ePoster will be made available on ECTRIMS platform beginning Wednesday, September 24th and will remain available for 3 months after the congress endsAbstract Number/ePoster Number: ECTRIMS25-1575/P1699Lead Author: Barry A. Singer, MD - Director, The MS Center for Innovations in Care - Missouri Baptist Medical Center, St. Louis, MO, United StatesePoster Presentation: Real-World Clinical Experience from ENABLE: the First Phase 4 Observational Study for Patients with Relapsing Multiple Sclerosis Initiating UblituximabPresentation Date/Time: ePoster will be made available on ECTRIMS platform beginning Wednesday, September 24th and will remain available for 3 months after the congress endsAbstract Number/ePoster Number: ECTRIMS25-1597/P1833Lead Author: Dr. Carrie Hersh, DO - Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, United StatesFollowing the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company's website at www.tgtherapeutics.com/publications.cfm.ABOUT THE ULTIMATE I & II PHASE 3 TRIALSULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four hours, 450 mg two weeks after the first infusion administered in one hour, and 450 mg every 24 weeks administered in one hour, with oral placebo administered daily; or teriflunomide, the active comparator, given orally as a 14 mg daily dose with IV placebo administered on the same schedule as BRIUMVI. Both studies enrolled patients who had experienced at least one relapse in the previous year, two relapses in the previous two years, or had the presence of a T1 gadolinium (Gd)-enhancing lesion in the previous year. Patients were also required to have an Expanded Disability Status Scale (EDSS) score from 0 to 5.5 at baseline. The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries. These trials were led by Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University. Additional information on these clinical trials can be found at www.clinicaltrials.gov (NCT03277261; NCT03277248).ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IVBRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses.BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and UK for the treatment of adult patients with RMS with active disease defined by clinical or imaging features.A list of authorized specialty distributors can be found at www.briumvi.com.IMPORTANT SAFETY INFORMATIONContraindications: BRIUMVI is contraindicated in patients with:Active Hepatitis B Virus infectionA history of life-threatening infusion reaction to BRIUMVIWARNINGS AND PRECAUTIONSInfusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within ...Full story available on Benzinga.com